<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072080</url>
  </required_header>
  <id_info>
    <org_study_id>EBSI-CV-317-004</org_study_id>
    <nct_id>NCT05072080</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317</brief_title>
  <acronym>CHIKV VLP</acronym>
  <official_title>A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this multi-center, randomized, double blind, placebo controlled study is to&#xD;
      evaluate the safety and immunogenicity of PXVX0317 in healthy adult and adolescent subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To evaluate the safety of PXVX0317 in healthy adult and adolescent subjects 12 to &lt;65&#xD;
           years of age.&#xD;
&#xD;
        2. To compare the chikungunya virus (CHIKV) serum neutralizing antibody (SNA) response to&#xD;
           PXVX0317 and placebo at Day 22, as measured by geometric mean titer (GMT) and clinically&#xD;
           relevant difference in seroresponse rate.&#xD;
&#xD;
        3. To demonstrate the consistency of the CHIKV SNA response across three lots of PXVX0317&#xD;
           at Day 22.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To compare the CHIKV SNA response to PXVX0317 and placebo at Day 8, Day 15, and Day 183.&#xD;
&#xD;
        2. To compare the CHIKV SNA response to PXVX0317 and placebo in subjects 12 to &lt;18 years of&#xD;
           age, subjects 18 to &lt;46 years of age, and subjects 46 to &lt;65 years of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 2:2:2:1 ratio within each age stratum (12 to &lt;18, 18 to &lt;46, and 46 to &lt;65). This study will be conducted in the US, using up to 50 sites.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of solicited Adverse Events (AE)</measure>
    <time_frame>8 days</time_frame>
    <description>Incidence of solicited AEs through Day 8 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsolicited AEs</measure>
    <time_frame>29 days</time_frame>
    <description>Incidence of unsolicited AEs through Day 29 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events of Special Interest (AESI)</measure>
    <time_frame>183 days</time_frame>
    <description>Incidence of AESIs, through Day 183 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Medically Attended Adverse Event (MAAE)</measure>
    <time_frame>183 days</time_frame>
    <description>Incidence of MAAEs through Day 183 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Event (SAE)</measure>
    <time_frame>183 days</time_frame>
    <description>Incidence of SAEs through Day 183 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHIKV serum neutralizing antibody (SNA) seroresponse rates at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>CHIKV SNA seroresponse rates for PXVX0317 and placebo, difference (PXVX0317 minus placebo), and associated 95% confidence interval (CI) at Day 22 for the IEP population, all age strata combined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHIKV SNA geometric mean titers (GMT) at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>CHIKV SNA GMTs and associated 95% CIs at Day 22 for PXVX0317 and placebo for the IEP population, all age strata combined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHIKV SNA GMT ratios between pairs of PXVX0317 lots at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>CHIKV SNA GMT ratios and associated 95% CIs between all three pairs of PXVX0317 lots (A:B, A:C, B:C) in adults 18 to &lt;46 years of age in the IEP population at Day 22.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CHIKV SNA seroresponse rates at Days 8, 15, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>CHIKV SNA seroresponse rates for PXVX0317 and placebo, difference (PXVX0317 minus placebo), and associated 95% CIs at Day 8, Day 15, and Day 183 for the IEP population, all age strata combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>CHIKV SNA GMTs with associated 95% CIs at Day 8, Day 15, and Day 183 for PXVX0317 and placebo for the IEP population, all age strata combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) in CHIKV SNA titers from Day 1 to Days 8, 15, 22, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>Geometric mean fold increase (GMFI) in CHIKV SNA titers from Day 1 to Day 8, Day 15, Day 22, and Day 183 for the IEP population for all age strata combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with CHIKV SNA titers at or above selected thresholds at Days 8, 15, 22, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>Number and percentage of subjects with CHIKV SNA titers ≥15, 60, 100, 160, 640, and 4-fold rise over baseline thresholds at Day 8, Day 15, Day 22, and Day 183 for the IEP population for all age strata combined.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3150</enrollment>
  <condition>Chikungunya Virus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 - PXVX0317 lot A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - PXVX0317 lot B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 - PXVX0317 lot C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 4 - Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIKV VLP/adjuvant</intervention_name>
    <description>PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on Alhydrogel® adjuvant 2%</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is comprised of formulation buffer</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide informed consent (and assent, as applicable) voluntarily&#xD;
             signed by subject (and guardian, as applicable).&#xD;
&#xD;
          -  Males or females, 12 to &lt;65 years of age.&#xD;
&#xD;
          -  Generally healthy, in the opinion of the Investigator, based on medical history,&#xD;
             physical examination, and screening laboratory assessments.&#xD;
&#xD;
          -  Women who are either: (i) Not of childbearing potential (CBP): pre-menarche,&#xD;
             surgically sterile (at least six weeks post bilateral tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy), or post-menopausal (defined as a history of ≥12&#xD;
             consecutive months without menses prior to randomization in the absence of other&#xD;
             pathologic or physiologic causes, following cessation of exogenous sex-hormonal&#xD;
             treatment) or (ii) Meeting all the below criteria: Negative serum pregnancy test at&#xD;
             screening visit, Negative urine pregnancy test immediately prior to dosing at Day 1,&#xD;
             Using an acceptable method of contraception (if women of CBP) for the duration of&#xD;
             participation, such as hormonal contraceptives (e.g., implants, pills, patches)&#xD;
             initiated ≥30 days prior to dosing, intrauterine device (IUD) inserted ≥30 days prior&#xD;
             to dosing, double barrier type of birth control (male condom with female diaphragm,&#xD;
             male condom with cervical cap).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant, breastfeeding, or planning to become pregnant during the study.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥35 kg/m2.&#xD;
&#xD;
          -  Positive laboratory evidence of current infection with human immunodeficiency virus&#xD;
             (HIV-1, HIV-2), hepatitis C virus (HCV) or hepatitis B virus (HBV).&#xD;
&#xD;
          -  History of severe allergic reaction or anaphylaxis to any component of the vaccine.&#xD;
&#xD;
          -  History of any known congenital or acquired immunodeficiency that could impact&#xD;
             response to vaccination (e.g., leukemia, lymphoma, generalized malignancy, functional&#xD;
             or anatomic asplenia, alcoholic cirrhosis).&#xD;
&#xD;
          -  Prior receipt or anticipated use of systemic immunomodulatory or immunosuppressive&#xD;
             medications from six months prior to screening through Day 22. Note: For systemic&#xD;
             corticosteroids, use at a dose or equivalent dose of 20 mg of prednisone daily for 14&#xD;
             days or more within three months of screening through Day 22 is exclusionary. The use&#xD;
             of inhaled, intranasal, topical, ocular, or intraocular steroids is allowed.&#xD;
&#xD;
          -  Receipt or anticipated receipt of blood or blood-derived products from 90 days prior&#xD;
             to screening through Day 22.&#xD;
&#xD;
          -  Acute disease within the last 14 days (subjects with an acute mild febrile illness can&#xD;
             be considered for a deferral of vaccination two weeks after the illness has resolved&#xD;
             and treatment has been completed).&#xD;
&#xD;
          -  Clinically significant cardiac, pulmonary, rheumatologic, or other chronic disease, in&#xD;
             the opinion of the Investigator. This may include chronic illness requiring&#xD;
             hospitalization in the last 30 days prior to screening.&#xD;
&#xD;
          -  Enrollment in an interventional study and/or receipt of another investigational&#xD;
             product from 30 days prior to screening through the duration of study participation.&#xD;
&#xD;
          -  Receipt or anticipated receipt of any vaccine from 30 days prior to screening through&#xD;
             Day 22.&#xD;
&#xD;
          -  Evidence of substance abuse that, in the opinion of the Investigator, could adversely&#xD;
             impact the subject's participation or the conduct of the study.&#xD;
&#xD;
          -  Prior receipt of an investigational CHIKV vaccine/product.&#xD;
&#xD;
          -  Any other medical condition that, in the opinion of the Investigator, could adversely&#xD;
             impact the subject's participation or the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Ajiboye, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Young</last_name>
    <phone>650-486-0273</phone>
    <email>youngp1@ebsi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Morales</last_name>
    <phone>204-275-4172</phone>
    <email>moralesm@ebsi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research - Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Garner</last_name>
      <email>lauren.garner@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>Harry Studdard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johnson County ClinTrials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manyvohn Rinehart</last_name>
      <phone>913-825-4400</phone>
      <email>mrinehart@jcct.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary Easley</last_name>
      <phone>913-825-4400</phone>
      <email>measley@jcct.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Fierro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research - Wichita East</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Hiebert</last_name>
      <email>Jill.hiebert@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Ward</last_name>
      <phone>816-943-0770</phone>
      <email>deb.ward@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>John Ervin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savannah Butt</last_name>
      <email>SButt@aventivresearch.com</email>
    </contact>
    <investigator>
      <last_name>Samir Arora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Heinzig-Cartwright</last_name>
      <email>dheinzig@lhsi.net</email>
    </contact>
    <investigator>
      <last_name>Carl Griffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kat Pratt</last_name>
      <email>kpratt@coastalcarolinaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Cynthia Strout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick C O'Keefe</last_name>
      <email>pokeefe@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Barbara Rizzardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chikungunya</keyword>
  <keyword>VLP</keyword>
  <keyword>PXVX0317</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

